drugset / Trial / NCT03499041
A Study of LY3314814 in Participants With Liver Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.
Timeline
- Start
- 2018-06
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped: “Stopped for futility. Phase 3 studies not likely to meet primary endpoints.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanabecestat | Small molecule | — | Oral |
Indications
No indication recorded.